Introduction
Progestin therapy serves as the primary fertility-sparing treatment for women diagnosed with atypical endometrial hyperplasia (AEH) and early-stage endometrioid endometrial cancer (EEC). While effective for many, approximately 15–25% of patients fail to achieve a complete response (CR), ultimately requiring definitive surgery and the subsequent loss of fertility. Metformin, a well-established biguanide used for type 2 diabetes, has emerged as a potential adjunctive therapy due to its anti-cancer properties and metabolic benefits. This review examines the current evidence regarding the combination of metformin and progestin in fertility-preserving oncology.
The Clinical Challenge
For young women desiring childbearing, the standard of care involves high-dose progestins to reverse endometrial lesions. However, this treatment often induces side effects such as weight gain, which can worsen the metabolic dysfunction—including obesity and insulin resistance—that frequently drives the development of endometrial cancer. There is a critical need for supplemental treatments that can improve CR rates, reduce recurrence, and manage the underlying metabolic risk factors.
Molecular Mechanisms of Metformin
Metformin exerts its anti-tumor effects through several key pathways:
- Pathway Inhibition: It inhibits the PI3K-AKT-mTOR signaling pathway, which is frequently dysregulated in endometrial cancer.
- AMPK Activation: By activating adenosine monophosphate-activated protein kinase (AMPK), metformin induces tumor suppressor genes and inhibits cell proliferation.
- Progesterone Sensitization: Crucially, metformin may increase the expression of progesterone receptors (PR) in endometrial tissues, potentially overcoming progestin resistance and enhancing the efficacy of the primary treatment.
Clinical Outcomes: Complete Response and Relapse
The clinical evidence for metformin's efficacy remains mixed. In a notable Phase II randomized controlled trial (RCT) of 150 patients, the combination of metformin and megestrol acetate showed a borderline-significantly higher CR rate at 16 weeks (34.3%) compared to megestrol acetate alone (20.7%). However, this statistical advantage diminished by the 32-week mark as the control group caught up.
The most compelling data involves cancer relapse. Meta-analyses and retrospective studies suggest that metformin may significantly reduce recurrence rates. One study reported a relapse rate of 17.4% in metformin users versus 25% in non-users, with a pooled odds ratio of 0.46 across multiple studies. This suggests that metformin may be particularly effective as a maintenance therapy to prevent the return of disease after initial clearance.
Fertility and Safety
Current data do not show a significant difference in pregnancy outcomes between patients receiving metformin and those who do not (approximately 48% vs. 42% in clinical trials). From a safety perspective, metformin is generally well-tolerated. The most frequent adverse effects are mild gastrointestinal issues, such as grade 1-2 diarrhea, which typically do not require treatment discontinuation.
Limitations and Future Directions
The current body of research is limited by high heterogeneity in study design, including varying metformin dosages (ranging from 500mg to 2250mg daily), inconsistent treatment durations, and small sample sizes. Furthermore, the frequent use of hysteroscopy for lesion removal may confound results by surgically eliminating the tissue that the pharmacological intervention is intended to treat.
High-quality, large-scale Phase III trials, such as the ongoing FELICIA trial, are essential to validate these findings. Future research must establish standardized dosing protocols and determine whether specific patient subgroups (e.g., those with high BMI or insulin resistance) benefit more from adjunctive metformin therapy.
Conclusion
While metformin shows promise as a multi-pronged adjunctive therapy for AEH and EEC, there is currently insufficient evidence to recommend its routine use in fertility-preserving protocols. Its potential to reduce relapse rates and improve metabolic health is significant, but definitive clinical recommendations await the results of more robust, well-powered trials.
Summary updated